- Report
- December 2023
- 200 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2428EUR$2,500USD£2,095GBP
- Clinical Trials
- April 2024
- 110 Pages
Global
From €1457EUR$1,500USD£1,257GBP
- Clinical Trials
- April 2024
- 70 Pages
Global
From €1457EUR$1,500USD£1,257GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1214EUR$1,250USD£1,047GBP
- Report
- October 2023
- 190 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Report
- September 2022
- 30 Pages
Global
From €3157EUR$3,250USD£2,723GBP
- Drug Pipelines
- September 2022
- 30 Pages
Global
From €3157EUR$3,250USD£2,723GBP
- Report
- August 2022
- 161 Pages
Global
From €7284EUR$7,500USD£6,284GBP
- Report
- January 2022
- 419 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Report
- December 2020
- 60 Pages
Global
From €3157EUR$3,250USD£2,723GBP
- Report
- November 2021
- 101 Pages
Global
From €4371EUR$4,500USD£3,770GBP
- Report
- February 2018
- 23 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Drug Pipelines
- February 2018
- 23 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Drug Pipelines
- July 2022
- 71 Pages
Global
From €6794EUR$6,995USD£5,861GBP
- Drug Pipelines
- August 2020
- 90 Pages
Global
From €1943EUR$2,000USD£1,676GBP
- Report
- April 2023
- 109 Pages
Global
€3399EUR$3,500USD£2,933GBP
- Report
- January 2024
- 105 Pages
Global
From €3500EUR$3,860USD£3,125GBP
- Drug Pipelines
- June 2021
- 95 Pages
Global
From €1943EUR$2,000USD£1,676GBP
Benralizumab is a monoclonal antibody used to treat severe asthma. It is a type of biologic drug, which works by targeting and blocking a specific protein in the body that is involved in the inflammation process. Benralizumab is administered as an intravenous infusion and is used in combination with other asthma medications. It is approved for use in adults and adolescents aged 12 years and older.
Benralizumab is used to treat severe asthma that is not adequately controlled with inhaled corticosteroids and long-acting beta-agonists. It is also used to reduce the frequency of exacerbations in patients with severe asthma. Benralizumab is a relatively new drug and is still being studied to determine its long-term safety and efficacy.
In the Benralizumab market, some of the major players include AstraZeneca, GlaxoSmithKline, Sanofi, and Teva Pharmaceuticals. Other companies involved in the market include Boehringer Ingelheim, Merck, and Novartis. Show Less Read more